NYSE: JNJ · General Drug Manufacturers

Johnson & Johnson (JNJ) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Johnson & Johnson (JNJ) at $226.25 a share. The stock last closed at $282.55, which puts the model's fair value 19.9% below the price. On the model's bands that reads as Overvalued.

Revalued . Price is the close of 16 Nov 2026. Johnson & Johnson.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$226.25midpoint of 2,000 simulations
Last close$282.55NYSE: JNJ
Gap to fair value-19.9%fair value against price
Model verdictOvervaluedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 held the fair value at $226.25, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $282.55 is 19.9% above it: Overvalued, on a high evidence grade.

What's nextReports on 20 Jan 2027. Options prices imply a move of about 8% either way over the next month. On the model's Quality Momentum list since 11 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give JNJ?

The calibrated range for JNJ over 63 trading days is $259.00 to $309.60. It sits around the last close, and its width comes from the volatility that JNJ's own options imply (26% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $181.10 to $280.77. In 18% of the simulations the fair value came out above the price the model ran on.

$134.89$374.21
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $226.25. Dashed line: the last close, $282.55.

Faircurve Insights · 14 Nov 2026

Johnson & Johnson is a holding company. It engages in the research, development, manufacture and sale of products in the healthcare field, through its Innovative Medicine and MedTech segments.

Faircurve's model put the fair value at $226.25 a share on 14 Nov 2026. That is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $226.48, so the fair value moved -0.1%. The calibrated range over 63 trading days is $259.00 to $309.60. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices, using 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

Johnson & Johnson scores 66 out of 100 on quality against comparable companies. The score is a composite of six factors. Balance sheet is the highest at 91, with net debt to EBITDA of 1.03x against a peer median of 1.27x. Stability scores 78, with five-year EBITDA margin downside volatility of 3.5 points against a peer median of 5.6 points. Earnings quality scores 71, with free cash flow to net income of 1.28x against a peer median of 1.17x. The model compares the company with eight others, including AbbVie, Merck, Eli Lilly and Pfizer, each with its own fair value on the site.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does JNJ report earnings, and how has the stock reacted?

Johnson & Johnson's next earnings report is scheduled for 20 Jan 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 3.6% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. JNJ's 30 day implied volatility works out to about 7.6% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across JNJ's last 8 reports, ignoring direction, was 0.7%.

0%5%3.0%1.0%22 Jan '253.7%0.3%15 Apr '253.1%5.0%16 Jul '253.9%0.1%14 Oct '254.0%0.1%21 Jan '264.4%0.3%14 Apr '264.4%1.5%15 Jul '264.2%3.7%13 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in JNJ

0%5%10%15%13 Oct '26 report15 Jul '26 report14 Apr '26 report21 Jan '26 report8% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 5% on 14 Nov 2025, reached 9% on 27 Mar 2026 and reads 8% on 16 Nov 2026. The marks are report dates.

How does JNJ score on business quality?

Johnson & Johnson's overall quality score is 66 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.5620.8%ROIC20.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).711.28xFCF / net income1.17x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.646.0%Revenue growth, trailing5.5%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.501.1%Net buybacks / market value0.3%
Balance sheetNet debt to EBITDA and interest coverage.911.03xNet debt / EBITDA1.27x
StabilityDownside volatility of the EBITDA margin over the last five years.783.5 ptsEBITDA margin downside volatility, 5y5.6 pts

How does JNJ compare with similar companies?

The companies in general drug manufacturers closest to Johnson & Johnson in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
ABBV AbbVie Inc.$294.55$298.37+1.3%Fairly valued
MRK Merck & Co., Inc.$144.46$126.11-12.7%Fairly valued
LLY Eli Lilly and Company$1,431.67$1,125.83-21.4%Overvalued
AMGN Amgen Inc.$462.32$479.14+3.6%Fairly valued
GILD Gilead Sciences, Inc.$167.58$219.16+30.8%Undervalued
PFE Pfizer Inc.$28.86$33.13+14.8%Fairly valued
BMY Bristol-Myers Squibb Company$62.93$68.95+9.6%Fairly valued
BIIB Biogen Inc.$251.65$256.53+1.9%Fairly valued

What the comparable companies' multiples alone would give for JNJ, the peer-implied price, is $150.41 a share on this run. The fair value weighs that against the company's own multiple.

All general drug manufacturer stocks ranked by gap to fair value

Johnson & Johnson at a glance

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

Market value
$687.9B
Sector
Healthcare
Industry
General Drug Manufacturers
Revenue expected, next twelve months
$107.0B
Consensus revenue growth, next fiscal year
+7.5%
Analysts with estimates
11
Beta to the US market
-0.14
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. JNJ was not among them.

How the fair value is worked out: the model prices Johnson & Johnson on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for JNJ was $226.48. As of 14 Nov 2026 it is $226.25, a change of -0.1%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Johnson & Johnson's valuation

Is Johnson & Johnson stock undervalued or overvalued?

On Faircurve's model, JNJ reads as Overvalued as of 14 Nov 2026. The model's fair value is $226.25 a share against a last close of $282.55, a gap of -19.9%.

What is JNJ's fair value?

$226.25 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $181.10 to $280.77.

What price range does the model give JNJ?

$259.00 to $309.60 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Johnson & Johnson report earnings next?

The next report is scheduled for 20 Jan 2027. Companies can move their dates.

How much has JNJ moved on past earnings reports?

Across its last 8 reports the median two session move was 0.7%, ignoring direction. The largest was +5.0% around the report of 16 Jul 2025.

How confident is the model in this valuation?

The model's evidence grade for JNJ is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on JNJ

The model has an idea open on JNJ under Quality Momentum since 11 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on JNJ with their outcomes. A free account is enough.

Keep reading